Asset / Drug

Ophthalmology

Drug and asset intelligence for Ophthalmology with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 3
Catalysts: 0
Stage: Development stage unavailable

Sponsor company

Novartis →

Recent signals(3)

ClinicalJune 18, 2026

Genentech initiates study on progression of intermediate age-related macular degeneration

Genentech is conducting a multicenter observational study to assess disease progression in intermediate age-related macular degeneration over approximately 3 years.

CompetitiveJune 17, 2026

Novel Pra-peptide hydrogel shows promise for treating ocular inflammation

The Pra-ffd hydrogel demonstrated improved bioavailability and reduced ocular inflammation in preclinical models.

ClinicalJune 1, 2026

Zhuochuming® Trial Evaluates 3+T&E vs 3+PRN in Diabetic Macular Edema

A clinical trial is underway to compare the efficacy of Zhuochuming® using a 3+T&E regimen against a 3+PRN regimen in treating treatment-naïve patients with diabetic macular edema.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Therapeutic areas

Age-Related Macular Degeneration →

Diabetic Macular Edema →

Ocular Inflammation →

Ophthalmology →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.